We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03112174
Recruitment Status : Active, not recruiting
First Posted : April 13, 2017
Last Update Posted : September 10, 2022
Sponsor:
Collaborator:
Janssen Research & Development, LLC
Information provided by (Responsible Party):
Pharmacyclics LLC.

Brief Summary:
This Phase 3 multinational, randomized, double-blind study is designed to compare the efficacy and safety of the combination of ibrutinib and venetoclax vs. ibrutinib and placebo in subjects with MCL.

Condition or disease Intervention/treatment Phase
Mantle-Cell Lymphoma Drug: Ibrutinib Drug: Venetoclax Drug: Placebo Oral tablet to match Venetoclax Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 352 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Phase 3 Study of Ibrutinib in Combination With Venetoclax in Subjects With Mantle Cell Lymphoma
Actual Study Start Date : June 29, 2017
Estimated Primary Completion Date : August 31, 2023
Estimated Study Completion Date : August 31, 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lymphoma

Arm Intervention/treatment
Experimental: Safety Run-in Period

Subjects are enrolled into the open-label Safety Run-in Period to evaluate the occurrence of tumor lysis syndrome (TLS) and DLTs with the concurrent administration of ibrutinib and venetoclax.

Safety run-in phase for the study is closed to further enrollment as of 07-Nov-2018.

Drug: Ibrutinib
Administered orally once daily

Drug: Venetoclax
Administered orally once daily

Experimental: Phase 3: Ibrutinb + Venetoclax
Subjects will be randomized to receive ibrutinib and venetoclax/placebo until clinical disease progression or unacceptable toxicity
Drug: Ibrutinib
Administered orally once daily

Drug: Venetoclax
Administered orally once daily

Placebo Comparator: Phase 3: Ibrutinib + Placebo
Subjects will be randomized to receive ibrutinib and venetoclax/placebo until clinical disease progression or unacceptable toxicity
Drug: Ibrutinib
Administered orally once daily

Drug: Placebo Oral tablet to match Venetoclax
Administered orally once daily

Experimental: Treatment-naive

This open-label arm is designed to explore the efficacy and safety of the combination of ibrutinib and venetoclax in subjects with treatment-naive MCL.

Approximately 75 subjects (of which ~25 subjects with TP53 mutation) will be enrolled and treated with ibrutinib and venetoclax.

Drug: Ibrutinib
Administered orally once daily

Drug: Venetoclax
Administered orally once daily




Primary Outcome Measures :
  1. Occurrence of Tumor Lysis Syndrome (TLS) (Safety Run-in Period) [ Time Frame: Approximately 3 months after last subject enrolled into safety run-in portion ]
    To evaluate the occurrence of tumor lysis syndrome (TLS) with the concurrent administration of ibrutinib and venetoclax.

  2. Occurrence of Dose Limiting Toxicities (DLT) (Safety Run-in Period) [ Time Frame: Approximately 3 months after last subject enrolled into safety run-in portion ]
    To evaluate the occurrence of DLTs with the concurrent administration of ibrutinib and venetoclax.

  3. Number of Participants With Adverse Events (AEs) (Safety Run-in Period) [ Time Frame: Up to approximately 5 years ]
    An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent adverse events/treatment-emergent serious adverse events (TEAEs/TESAEs) are defined as any event that began or worsened in severity on or after the first dose of study drug.

  4. Overall response rate (ORR) (Safety Run-in Period) [ Time Frame: approximately 1 year after last subject has stopped treatment with study drug(s) ]
    ORR is defined as CR or PR per investigator assessment according to the Revised Response Criteria for Malignant Lymphoma.

  5. Duration of Response (DOR) (Safety Run-in Period) [ Time Frame: Up to approximately 5 years ]
    DOR is defined as participants who achieve an overall response as the time from the first occurrence of response (CR or PR) to disease progression or death, whichever occurs first.

  6. Progression-free Survival (PFS) (Safety Run-in Period) [ Time Frame: approximately 1 year after last subject has stopped treatment with study drug(s) ]
    To evaluate PFS of ibrutinib and venetoclax compared to ibrutinib and placebo.

  7. Overall Survival (OS) (Safety Run-in Period) [ Time Frame: Up to approximately 5 years ]
    OS is defined as the time from the date of the first dose of study treatment to death from any cause.

  8. Progression-free Survival (PFS) (Randomization Period) [ Time Frame: approximately 1 year after last subject has stopped treatment with study drug(s) ]
    To evaluate PFS of ibrutinib and venetoclax compared to ibrutinib and placebo.

  9. Complete Response (CR) (Treatment-Naive Arm) [ Time Frame: approximately 1 year after last subject has stopped treatment with study drug(s) ]
    To evaluate the complete response (CR) rate with the combination of ibrutinib and venetoclax in subjects with treatment-naive MCL


Secondary Outcome Measures :
  1. Complete Response (CR) (Randomization Period) [ Time Frame: approximately 1 year after last subject has stopped treatment with study drug(s) ]
    Complete response rate (CR) based on the best overall response per investigator assessment according to the Revised Response Criteria for Malignant Lymphoma.

  2. Overall response rate (ORR) (Randomization Period and Treatment-Naive Arm) [ Time Frame: approximately 1 year after last subject has stopped treatment with study drug(s) ]
    ORR is defined as CR or PR per investigator assessment according to the Revised Response Criteria for Malignant Lymphoma.

  3. MRD-negative remission rate in participants who achieve CR per investigator assessment (Randomization Period and Treatment-Naive Arm) [ Time Frame: approximately 1 year after last subject has stopped treatment with study drug(s) ]
    MRD-negative remission is defined as undetectable MRD at documented CR in subjects who were MRD positive at screening as assessed by flow cytometry in bone marrow and/or peripheral blood, with requirement of confirmation of MRD negativity in the subsequent peripheral blood 12 weeks later.

  4. Overall Survival (OS) (Randomization Period and Treatment-Naive Arm) [ Time Frame: Up to approximately 5 years ]
    OS is defined as the time from the date of the first dose of study treatment to death from any cause.

  5. Duration of Response (DOR) (Randomization Period and Treatment-Naive Arm) [ Time Frame: Up to approximately 5 years ]
    DOR is defined as participants who achieve an overall response as the time from the first occurrence of response (CR or PR) to disease progression or death, whichever occurs first.

  6. Time to Next Treatment (TTNT) (Randomization Period and Treatment-Naive Arm) [ Time Frame: Up to approximately 5 years ]
    TTNT is defined as the duration from the date of randomization to the start date of any anti-lymphoma treatment subsequent to study treatment.

  7. Percentage of participants experiencing Adverse Events (Randomization Period) [ Time Frame: Up to approximately 5 years ]
    An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.

  8. Occurrence of Tumor Lysis Syndrome (TLS) (Randomization Period) [ Time Frame: Approximately 3 months after last subject enrolled into safety run-in portion ]
    To evaluate the occurrence of tumor lysis syndrome (TLS) with the concurrent administration of ibrutinib and venetoclax.

  9. Cmax if Ibrutinib (Randomization Period) [ Time Frame: Week 6 ]
    Cmax if Ibrutinib.

  10. Tmax if Ibrutinib (Randomization Period) [ Time Frame: Week 6 ]
    Tmax if Ibrutinib.

  11. AUClast if Ibrutinib (Randomization Period) [ Time Frame: Week 6 ]
    AUClast if Ibrutinib.

  12. Half-Life (T1/2) if Ibrutinib (Randomization Period) [ Time Frame: Week 6 ]
    Half-Life (T1/2) if Ibrutinib.

  13. Cmax of Venetoclax (Randomization Period) [ Time Frame: Week 6 ]
    Cmax of Venetoclax.

  14. Tmax of Venetoclax (Randomization Period) [ Time Frame: Week 6 ]
    Tmax of Venetoclax.

  15. AUC of Venetoclax (Randomization Period) [ Time Frame: Week 6 ]
    AUC of Venetoclax.

  16. Time to worsening in FACT-Lym subscale of the health-related quality of life (Randomization Period) questionnaire (FACT-Lym) [ Time Frame: Week 6 ]
    Time to worsening in FACT-Lym subscale of the health-related quality of life questionnaire (FACT-Lym) will be compared between treatment arms.

  17. Duration of CR (Treatment-Naive Arm Period) [ Time Frame: Up to approximately 5 years ]
    Duration of CR, defined for subjects who achieve CR as the time from the first occurrence of CR to disease progression or death, whichever occurs first.

  18. Progression-free Survival (PFS) (Treatment-Naive Arm Period) [ Time Frame: approximately 1 year after last subject has stopped treatment with study drug(s) ]
    To evaluate PFS of ibrutinib and venetoclax compared to ibrutinib and placebo.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Relapsed/Refractory Arm

Inclusion Criteria:

  • Pathologically confirmed MCL (in tumor tissue), with documentation of either overexpression of cyclin D1 in association with other relevant markers (eg, CD19, CD20, PAX5, CD5) or evidence of t(11;14) as assessed by cytogenetics, fluorescent in situ hybridization (FISH), or polymerase chain reaction (PCR).
  • At least 1 measurable site of disease on cross-sectional imaging (CT/PET).
  • At least 1, but no more than 5, prior treatment regimens for MCL.
  • Failure to achieve at least partial response (PR) with, or documented disease progression after, the most recent treatment regimen.
  • Subjects must have adequate fresh or paraffin embedded tissue.
  • Adequate hematologic, hepatic and renal function.
  • Eastern Cooperative Oncology Group (ECOG) performance status (PS) of <= 2.

Exclusion Criteria:

  • History or current evidence of central nervous system lymphoma.
  • Concurrent enrollment in another therapeutic investigational study or prior therapy with ibrutinib or other BTK inhibitors.
  • Prior treatment with venetoclax or other BCL2 inhibitors.
  • Anticancer therapy including chemotherapy, radiotherapy, small molecule and investigational agents 21 days prior to receiving the first dose of study drug.
  • Treatment with any of the following within 7 days prior to the first dose of study drug: moderate or strong cytochrome P450 3A (CYP3A) inhibitors or strong CYP3A inducers.

Treatment Naïve Arm

Inclusion Criteria:

  • Pathologically confirmed treatment-naive MCL (tumor tissue), with documentation of either overexpression of cyclin D1 in association with other relevant markers (eg, CD19, CD20, PAX5, CD5) or evidence of t(11;14), as assessed by cytogenetics, fluorescent in situ hybridization (FISH), or polymerase chain reaction (PCR).
  • Men and women ≥18 years of age with a TP53 mutation.
  • At least 1 measurable site of disease.
  • Must have adequate fresh or paraffin-embedded tissue.
  • Eastern Cooperative Oncology Group (ECOG) performance status score 0-2.
  • Adequate hematologic, hepatic, and renal function.

Exclusion Criteria:

  • Blastoid variant of MCL
  • History or current evidence of CNS lymphoma.
  • Concurrent enrollment in another therapeutic investigational study or prior therapy including ibrutinib or other BTK inhibitors.
  • Prior treatment with venetoclax or other BCL2 inhibitors.
  • Vaccinated with live, attenuated vaccines within 4 weeks of the first dose of study drug.
  • Clinically significant infection requiring IV systemic treatment that was completed <=14 days before the first dose of study drug.
  • Any uncontrolled active systemic infection.
  • Known bleeding disorders (eg, von Willebrand's disease or hemophilia).
  • History of stroke or intracranial hemorrhage within 6 months prior to enrollment.
  • History of HIV or active HCV or HBV.
  • Major surgery within 4 weeks of the first dose of study drug.
  • Any life-threatening illness, medical condition, or organ system dysfunction that, in the investigator's opinion, could compromise the participant's safety or put the study outcomes at undue risk.
  • Currently active, clinically significant cardiovascular disease; or a history of myocardial infarction, unstable angina, or acute coronary syndrome within 6 months prior to randomization.
  • Unable to swallow capsules or tablets, or malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel, symptomatic inflammatory bowel disease or ulcerative colitis, or partial or complete bowel obstruction.
  • Treatment with any of the following within 7 days prior to the first dose of study drug: Moderate or strong cytochrome P450 3A (CYP3A) inhibitors or moderate or strong CYP3A inducers.
  • Known allergy to xanthine oxidase inhibitors and/or rasburicase for subjects with known risk factors (as defined by high tumor burden and/or diminished renal function, as detailed in "Study Design" section above) for TLS.
  • Chronic liver disease with hepatic impairment Child-Pugh class B or C.
  • Unwilling or unable to participate in all required study evaluations and procedures.
  • Known hypersensitivity to the active ingredient or other components of one or more study drugs.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03112174


Locations
Show Show 120 study locations
Sponsors and Collaborators
Pharmacyclics LLC.
Janssen Research & Development, LLC
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Pharmacyclics LLC.
ClinicalTrials.gov Identifier: NCT03112174    
Other Study ID Numbers: PCYC-1143-CA
2017-000129-12 ( EudraCT Number )
First Posted: April 13, 2017    Key Record Dates
Last Update Posted: September 10, 2022
Last Verified: September 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Pharmacyclics LLC.:
PCYC
MCL
Non-Hodgkin's Lymphoma
NHL
ibrutinib
venetoclax
Pharmacyclics
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma
Lymphoma, Mantle-Cell
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Lymphoma, Non-Hodgkin
Venetoclax
Antineoplastic Agents